Botox Brands in the US (2026): FDA-Approved Neurotoxins Guide

For med spa owners, medical directors and injectors. Updated October 11, 2026 · Prepared by Prospyr. Prospyr makes practice software for med spas, plastic surgery and wellness practices, not drugs, and none of the companies below is a Prospyr product or partner. This is a reference guide, not a ranking. Inclusion comes from U.S. Food and Drug Administration (FDA) prescribing information on Drugs@FDA, and each company summary reflects the manufacturer's own website, checked October 2026. This article is not medical advice and makes no claim about the safety, effectiveness or duration of any product. Confirm indications, storage and account terms with each company and the current label before you order.

Which Botox brands are FDA-approved?

"Botox" is the name most patients use for every wrinkle-relaxing injection, but BOTOX Cosmetic is one brand of botulinum toxin type A, made by Allergan Aesthetics, an AbbVie company. Six botulinum toxin products on Drugs@FDA carry an aesthetic indication in the US: BOTOX Cosmetic (onabotulinumtoxinA), DAXXIFY (daxibotulinumtoxinA-lanm), Dysport (abobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Letybo (letibotulinumtoxinA-wlbg) and XEOMIN (incobotulinumtoxinA). All six are approved for moderate to severe glabellar (frown) lines in adults. Some have more aesthetic indications, listed below. Every label carries the same boxed warning, "Distant Spread of Toxin Effect," and every label states that its units cannot be swapped for another product's units.

The 6 FDA-approved neurotoxin brands at a glance

How we chose this list

This guide has one inclusion rule: the product must be a botulinum toxin with an FDA-approved aesthetic indication on its prescribing information at Drugs@FDA, checked October 2026. We then loaded each company's own website to confirm who markets the product in the US, its loyalty or savings program, and how practices open an account.

• FDA approval first. Toxins approved only in other countries, or still under FDA review, are not included.
• Label facts only. Indications, vial sizes, storage and the boxed warning come from each product's FDA label.
• No head-to-head claims. We do not compare onset, duration, results or side-effect rates. The labels say units are not interchangeable, so we do not publish conversion ratios.
• Company terms only where published. None of the six publishes pricing on its public site.

Brands are listed alphabetically. The order is not a ranking or a measure of results.

1. BOTOX Cosmetic (Allergan Aesthetics)

Allergan Aesthetics, an AbbVie company, markets BOTOX Cosmetic (onabotulinumtoxinA) alongside the JUVÉDERM collection, SKINVIVE, KYBELLA, CoolSculpting, Natrelle and SkinMedica. The label lists an initial U.S. approval of 1989 for the active ingredient and four aesthetic indications in adults: moderate to severe glabellar lines, lateral canthal lines (crow's feet), forehead lines and platysma bands.

What stands out:

• Most aesthetic indications. It is the only toxin on this list approved for platysma bands, the vertical neck bands between the jaw and collarbone.
• Loyalty program. Patients earn through Allē, and BOTOX Cosmetic's provider search runs through Allē. See our guide to manufacturer loyalty programs.
• Provider resources. Allergan lists an HCP site, a provider product questions line and a "Placing an Order" page for practices.

Right for: practices that already buy Allergan fillers or devices, and patients who ask for the brand by name. Ask: how Allē points flow back to the practice, and what volume tiers apply to your account.

2. DAXXIFY (Revance)

DAXXIFY (daxibotulinumtoxinA-lanm) is marketed by Revance. Crown Laboratories' site states that "Crown Laboratories and Revance Therapeutics are now united as REVANCE." The FDA label lists an initial U.S. approval of 2022, with indications for moderate to severe glabellar lines in adults and for cervical dystonia.

What stands out:

• Formulation. Revance calls DAXXIFY "the first and only frown line treatment with a peptide formulation."
• Storage. The label allows unopened vials to be stored at room temperature (20°C to 25°C) or refrigerated, which is different from most toxins here.
• Dose. The label's glabellar dose is 40 Units across five sites. That number is specific to DAXXIFY units and cannot be compared with other brands.
• Savings program. Patients earn through REVA (Revance Rewards), Revance's patient loyalty program.

Right for: practices that want a second toxin with different storage handling. Ask: how the Crown and Revance combination changes your account contact, and what REVA offers your patients.

3. Dysport (Galderma)

Dysport (abobotulinumtoxinA) is made by Ipsen Biopharm in Wrexham, UK, and distributed in the US by Ipsen and Galderma Laboratories, according to its label. The aesthetic site carries Galderma's name and states the Dysport trademark is used under license. The label lists an initial U.S. approval of 2009. Its aesthetic indication is moderate to severe glabellar lines in adults younger than 65.

What stands out:

• Age limit on the label. The glabellar indication is for adults under 65, the only toxin here with that limit.
• Vial sizes. Dysport comes in 300 and 500 Unit vials, so your inventory counts look different from 50 and 100 Unit brands.
• Rewards. Patients earn through ASPIRE Galderma Rewards, which also covers Galderma's Restylane and Sculptra lines.

Right for: practices that also buy Restylane or Sculptra and want one rewards program across them. Ask: how ASPIRE is funded at the practice level and how Galderma handles reorders and returns.

4. Jeuveau (Evolus)

Evolus, based in Newport Beach, California, describes itself as "a performance beauty company" focused on the cash-pay aesthetics market. Jeuveau (prabotulinumtoxinA-xvfs) has an initial U.S. approval of 2019 for moderate to severe glabellar lines in adults. Evolus also sells Evolysse hyaluronic acid fillers.

What stands out:

• Patient programs. Evolus runs Evolus Rewards for patients, with a recurring per-treatment patient offer, and Club Evolus, a patient membership that covers 20 Units of Jeuveau per treatment (as of October 2026).
• Practice login. Practices create an account and log in through Evolus's practice portal.
• Single vial size. Jeuveau comes in 100 Unit vials.

Right for: cash-pay med spas that want a toxin company focused only on aesthetics. Ask: how Club Evolus memberships are billed and paid to the practice, and how they interact with your own membership program.

5. Letybo (Hugel Aesthetics)

Letybo (letibotulinumtoxinA-wlbg) is made by Hugel, Inc. in Chuncheon, Korea. The FDA label lists an initial U.S. approval of 2024 for moderate to severe glabellar lines in adults. The brand site's footer names Hugel America, Inc., and Hugel Aesthetics describes itself as the North American division of Hugel Inc., founded in Seoul in 2001 and present in more than 70 countries.

What stands out:

• Newest on the list. Letybo, with an initial U.S. approval of 2024, is the most recently approved toxin on this list.
• Ordering hub. Hugel describes the Hugel Hub as the place to place orders, view order history and download marketing materials.
• Provider locator. The patient-facing provider finder was marked "coming soon" when we checked, with a link for practices to request a listing.

Right for: practices open to adding a newer brand and building patient awareness themselves. Ask: who your US sales and clinical contact is, what training Hugel provides, and when the provider locator goes live.

6. XEOMIN (Merz Aesthetics)

XEOMIN (incobotulinumtoxinA) is made by Merz Pharmaceuticals GmbH in Frankfurt and distributed in the US by Merz Pharmaceuticals, LLC of Raleigh, North Carolina, and Merz North America, according to its label. The label lists an initial U.S. approval of 2010 and aesthetic indications in adults for moderate to severe glabellar lines, horizontal forehead lines and lateral canthal lines.

What stands out:

• Storage. The label says unopened vials are stored at or below 25°C and that refrigeration of unopened vials is not required.
• Formula. Merz describes XEOMIN as double filtered to remove complexing proteins, with a three-ingredient formula.
• Account portal and rewards. US practices sign in through the Merz Aesthetics Portal, and patients earn through Xperience+. Merz also sells Ultherapy and Radiesse.

Right for: practices that want a toxin with simple storage, or that already buy Ultherapy or Radiesse. Ask: which vial sizes your account can order for aesthetic use (the label lists 50 and 100 Unit cartons for upper facial lines; the 200 Unit vial is listed for therapeutic uses), and how Xperience+ savings are applied at checkout.

Not on this list

Galderma's relabotulinumtoxinA (Relfydess) did not have FDA approval when we checked in October 2026. We will add any newly approved toxin at the next quarterly review.

Questions to ask any neurotoxin company

1. What exactly is on the current label? Get the latest prescribing information and keep your marketing claims within the approved indications.
2. How are units counted and recorded? Every label says its units cannot be compared to or converted into units of other botulinum toxin products. Chart the brand and units for every area so the next provider does not guess.
3. How should vials be stored and tracked? Storage differs by brand. See our list of medical refrigerators and temperature monitoring.
4. What do volume tiers and rebates require? Ask for tier thresholds, rebate timing and what happens if you miss a quarter.
5. How does the loyalty program pay the practice? Ask who funds each patient offer and when credits reach your account.
6. What training and complication support comes with the account? Ask what the company provides, and keep your own plan. See our list of complication management courses.
7. How do we report an adverse event? Know the manufacturer's line and the FDA MedWatch route, both printed on every label.

Where Prospyr fits

Carrying two or three toxins means tracking which brand, lot and units went into each patient. Prospyr's inventory management keeps vial counts and lots in one place, the aesthetic EMR records brand and units by injection site so the next visit starts from the chart, and packages let you sell toxin as a series or membership. For your other supplies, see our list of aesthetic medical supply distributors, or book a practice demo.

Frequently asked questions

How many Botox brands are there?

Six botulinum toxin brands have an FDA-approved aesthetic indication in the US as of October 2026: BOTOX Cosmetic, DAXXIFY, Dysport, Jeuveau, Letybo and XEOMIN. Only BOTOX Cosmetic is Botox; the others are different botulinum toxin products from other companies.

Are units of different neurotoxin brands interchangeable?

No. Each FDA label states that its potency units are specific to that product and cannot be compared to or converted into units of any other botulinum toxin product. Dose by the label of the brand you are using.

Which neurotoxins can be stored without refrigeration?

Per their labels, unopened XEOMIN vials are stored at or below 25°C with no refrigeration required, and unopened DAXXIFY vials may be kept at room temperature or refrigerated. BOTOX Cosmetic, Dysport, Jeuveau and Letybo labels call for refrigerating unopened vials at 2°C to 8°C. Check each label for storage after reconstitution.

Which neurotoxin is approved for the most aesthetic areas?

BOTOX Cosmetic lists four aesthetic indications: glabellar, lateral canthal and forehead lines, and platysma bands. XEOMIN lists three. DAXXIFY, Dysport, Jeuveau and Letybo list glabellar lines only. Approval for an area is not a measure of results.

Is Relfydess FDA-approved?

Not as of October 2026. We found no FDA approval for Galderma's relabotulinumtoxinA when we checked.

Want your company considered?

We review this guide quarterly. Companies that market an FDA-approved botulinum toxin, or serve practices that use them, can send their website and what they offer practices to info@prospyrmed.com. Inclusion is editorial and not paid.

Editorial scope

This guide is based on FDA prescribing information on Drugs@FDA and each company's public website, checked October 2026 with AI-assisted research. Companies did not review this article before publication. It is not medical advice, a comparison of product safety or results, or a substitute for each product's FDA-approved labeling. Read our methodology or report a correction.